According to Stats Canada... “Migraine can be a debilitating disorder characterized by pulsating headaches lasting from a few hours to several days, accompanied by nausea, vomiting, and/or sensitivity to light and sound. It is exacerbated by and tends to interfere with physical activity. Migraine usually occurs on one side of the head, although in children and youth it tends to be bilateral. In 2010/2011, an estimated 8.3% of Canadians (2.7 million) reported that they had been diagnosed with migraine (Table 1). This likely underestimates migraine prevalence. Research indicates that some people who experience migraine do not seek professional help, and therefore, would not have a diagnosis to report.”
This review aims to take a look at the recent publications on the effectiveness and safety of cannabinoid-based migraine treatment, as well as studies of the mechanisms underlying therapeutic effects of these compounds. Based on our experience in experimental studies of migraine, we discuss our own and other available data on the potential applications of cannabinoid therapy in migraine treatment. Summary of review ” Cannabinoids – due to their anticonvulsive, analgesic, antiemetic, and anti-inflammatory effects – present a promising class of compounds for both acute and prophylactic treatment of migraine pain.” Read full Frontiers in Pharmacology Review